Amy Conner, OD
Optometrist · Houston, TXNPI 1558881276
Payments from drug & device makers
Across 107 payments — averaging $43.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$529
- AbbVie$527
- Bausch & Lomb Americas Inc.$513
- Glaukos Corporation$467
- Visionary Optics LLC$425
- Sun Pharmaceutical Industries Inc.$319
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$4,20890%
- Education$180%
- Gifts$4259%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 10 | $529 |
| AbbVie | 17 | $527 |
| Bausch & Lomb Americas Inc. | 11 | $513 |
| Glaukos Corporation | 5 | $467 |
| Visionary Optics LLC | 1 | $425 |
| Sun Pharmaceutical Industries Inc. | 9 | $319 |
| Tarsus Pharmaceuticals, Inc. | 7 | $283 |
| Rxsight Inc | 6 | $282 |
| Dompe US, Inc. | 6 | $193 |
| Harrow Eye, LLC | 4 | $190 |
| Novartis | 7 | $175 |
| Amgen(2 entities) | 2 | $148 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $146 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Alcon | 5 | $109 |
| Aerie Pharmaceuticals, Inc. | 3 | $60 |
| Ocular Therapeutix, Inc. | 2 | $53 |
| Oyster Point Pharma, Inc. | 3 | $51 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $37 |
| Eyevance Pharmaceuticals LLC | 2 | $29 |
| Thea Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$248
- DURYSTA$227
- iStent Infinite$179
- iDoseTR$179
- RXSIGHT CONTACT LENS$135
- RXSIGHT INJECTOR CARTRIDGE$135
- RXSIGHT INJECTOR HANDPIECE$135
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$135
- LIGHT ADJUSTABLE LENS (LAL)$135
- iStent inject Trabecular Micro-Bypass Stent System$128
- Photrexa$128
- EYSUVIS$125
- TEPEZZA$125
- VYZULTA$125
- VEVYE$125
- XIIDRA$123
- Oxervate$110
- XDEMVY$110
How this compares
$4,676 in reported general payments places this provider in the 90th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 60 | $64,225 |
| MieboPerfluorohexyloctane/Pf | 26 | $21,652 |
| LumiganBimatoprost | 33 | $19,043 |
| XiidraLifitegrast | 11 | $15,908 |
| Cyclosporine | 43 | $15,388 |
| VevyeCyclosporine | 14 | $10,576 |
| TobradexTobramycin/Dexamethasone | 24 | $6,240 |
| Prednisolone Acetate | 123 | $5,854 |
| Loteprednol Etabonate | 34 | $4,978 |
| Brimonidine Tartrate | 21 | $4,946 |
| Travoprost | 24 | $4,824 |
| Brinzolamide | 20 | $4,663 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 160 | $3,727 |
| LotemaxLoteprednol Etabonate | 11 | $3,678 |
| Fluorometholone | 58 | $3,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $527 | $83,26893 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $513 | $37,56037 claims |
| Harrow Eye, LLCVevye | $190 | $10,57614 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax | $37 | $8,65645 claims |
| Eyevance Pharmaceuticals LLCFlarex | $29 | $2,73222 claims |
| AlconSimbrinza | $109 | $2,67911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Houston
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Kathryn RichdaleHouston$288K
- Nancy StephensHouston$241K
- Jelita Green-DathorneHouston$232K
- Eric RitcheyHouston$151K
- Maria WalkerHouston$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.